Vertex Pharmaceuticals Drops 3.22% Amid Revenue Guidance

Vertex Pharmaceuticals Incorporated, a global biotechnology company, experienced a 3.22% drop in pre-market trading on April 9, 2025. The company, founded in 1989, is dedicated to discovering, developing, producing, and commercializing small molecule drugs for serious diseases in specialized markets. Vertex has two key products, KALYDECO and INCIVEK, and collaborates with leading pharmaceutical companies, non-profit disease research institutions, and renowned academic institutions worldwide.

Vertex Pharmaceuticals has been guiding for revenue between $11.75 billion and $12.0 billion for 2025, representing a 9% annual increase at the midpoint. This growth is driven by the company's strong pipeline and successful commercialization of its existing products. The company's estimated fair value is US$797 based on a 2 Stage Free Cash Flow to Equity model, suggesting potential upside from the current share price.

Analysts have a generally positive outlook on Vertex Pharmaceuticals. According to 25 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $508.09, which is an increase of 5.93% from the current price. This optimistic view is supported by the company's robust pipeline and its track record of delivering innovative therapies to patients with serious diseases.